<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02468778</url>
  </required_header>
  <id_info>
    <org_study_id>HeartMate PHP™ SHIELD II</org_study_id>
    <nct_id>NCT02468778</nct_id>
  </id_info>
  <brief_title>Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)</brief_title>
  <acronym>SHIELD II</acronym>
  <official_title>Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HeartMate PHP System is a temporary (&lt;6 hours) ventricular assist device indicated for
      use during high-risk percutaneous coronary interventions (PCI) performed electively or
      urgently in hemodynamically stable patients with severe coronary artery disease, when a heart
      team, including a cardiac surgeon, has determined high-risk PCI is the appropriate
      therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent
      hemodynamic instability, which can result from repeat episodes of reversible myocardial
      ischemia that occur during planned temporary coronary occlusions and may reduce peri-and
      post-procedural adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomized, multi-center, open-label trial of the HeartMate PHP at up to 120
      sites in the US and Europe. Control device will be any Abiomed Impella device approved for
      use in high-risk PCI.

      This clinical investigation is divided into two phases, a feasibility phase and a pivotal
      phase.

        -  Feasibility Phase: Includes 75 roll-in and 120 randomized subjects registered under the
           CIP versions 2-4 at 48 sites in the United States (U.S.) prior to January 30, 2017

        -  Pivotal Phase: Includes subjects to be registered under Version F or a later version of
           the CIP at up to 120 sites in the U.S. and Europe

      Non-randomized Roll-in Cohort: Up to 480 subjects with the HeartMate PHP.

      Randomized Cohort: A minimum of 473 and a maximum of 716 subjects will be randomized in a 2:1
      ratio to the HeartMate PHP and Impella.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of participants with cardiovascular death, myocardial infarction, stroke, any unplanned repeat revascularization, bleeding (BARC 3 or 5), severe hypotension, or increase in aortic insufficiency from baseline to 90 days.</measure>
    <time_frame>90 Days</time_frame>
    <description>The primary endpoint is a composite endpoint. Rate of participants having any of below mentioned events will be recorded.
Cardiovascular death
Myocardial infarction
Stroke
Any unplanned repeat revascularization (PCI or CABG)
Bleeding (BARC 3 or 5)
Severe hypotension
Increase in aortic insufficiency from baseline to 90 days
Note: Individual events will be recorded as separate endpoint under secondary outcome measures (as mentioned below).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of participants with cardiovascular death</measure>
    <time_frame>90 Days</time_frame>
    <description>Cardiovascular death includes sudden cardiac death, death due to acute myocardial infarction, death due to heart failure or cardiogenic shock, death due to stroke, death due to other cardiovascular causes, and death due to bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants with myocardial Infarction</measure>
    <time_frame>90 Days</time_frame>
    <description>Periprocedural MI (≤ 48 hours post PCI)
Spontaneous MI &gt; 48 hours post PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants with stroke</measure>
    <time_frame>90 Days</time_frame>
    <description>Cerebral infarction occurring within 90 days after device use as measured by clinical assessment and/or diagnostic imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants with any unplanned repeat revascularization (PCI or CABG)</measure>
    <time_frame>90 Days</time_frame>
    <description>Additional unplanned PCI or CABG surgery occurring within 90 days after device use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants with bleeding (BARC category 3 or 5)</measure>
    <time_frame>90 Days</time_frame>
    <description>Major bleeding (BARC category 3 or 5) occurring within 90 days after device use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants with severe hypotension</measure>
    <time_frame>90 Days</time_frame>
    <description>Systolic blood pressure or augmented diastolic pressure (whichever is greater) &lt;90 mmHg while on device support requiring (1) more than one administration of OR (2) continuous infusion of inotropic/pressor medications to restore hemodynamics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants with increase in aortic insufficiency from baseline to 90 days</measure>
    <time_frame>90 Days</time_frame>
    <description>Aortic insufficiency will be assessed by echocardiogram (done by the core lab), looking at the increase in aortic regurgitation from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants with all-cause death</measure>
    <time_frame>90 Days</time_frame>
    <description>Death due to any cause occurring within 90 days of device use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic measure: Maximal change in cardiac power output (CPO) from pre-PCI while on device support</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>CPO as calculated from mean arterial pressure and cardiac output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic measure: Maximal change in central venous pressure (CVP) from pre-PCI while on device support</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>CVP as measured by direct right heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic measure: Maximal change in mean arterial pressure (MAP) from pre-PCI while on device support</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>MAP as measured by direct right heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic measure: Maximal change in pulmonary artery pressure (PAP) from pre-PCI while on device support</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>PAP as measured by direct right heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic measure: Maximal change in pulmonary capillary wedge pressure (PCWP) from pre-PCI while on device support</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>PCWP as measured by direct right heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic measure: Maximal change in cardiac output (CO) from pre-PCI while on device support</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>CO as measured by direct right heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic measure: Maximal change in cardiac index (CI) from pre-PCI while on device support</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>CI as measured by direct right heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants with device-related access site complication requiring intervention or device-related limb ischemia</measure>
    <time_frame>90 Days</time_frame>
    <description>Major and minor vascular complications, including those due to percutaneous closure device failure occurring within 90 days of device use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants with surgical intervention due to device complication or malfunction</measure>
    <time_frame>90 Days</time_frame>
    <description>Any device complication or malfunction requiring surgical intervention for resolution within 90 days of device use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>Hospital Discharge</time_frame>
    <description>Number of hospital days associated within the initial study hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit (ICU) days</measure>
    <time_frame>Hospital Discharge</time_frame>
    <description>Number of ICU days associated within the initial study hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants with increase in aortic insufficiency from baseline to post-procedure and/or from baseline to discharge</measure>
    <time_frame>At the time of post-procedure (within 48 hours post device removal) and again at the time of hospital discharge (typically within one week after the procedure)</time_frame>
    <description>Aortic insufficiency will be assessed by echocardiogram (done by the core lab), looking at the increase in aortic regurgitation from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lactate dehydrogenase (LDH) from pre-device insertion to post-device removal</measure>
    <time_frame>Intraprocedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma-free hemoglobin (PfHgb) from pre-device insertion to post-device removal</measure>
    <time_frame>Intraprocedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success (at exit from catheterization lab)</measure>
    <time_frame>At the time of procedure completion (typically within 6 hours after the study device is inserted)</time_frame>
    <description>- Alive, with:
Successful access, delivery, function and retrieval of the device, and
No need for additional unplanned or emergency surgery or re-intervention related to the device or access procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success (hospital discharge)</measure>
    <time_frame>At the time of hospital discharge (typically within one week after the procedure)</time_frame>
    <description>- Alive and stroke free with:
No peri-procedural MI or post-procedural spontaneous MI
No additional interventional or surgical procedures related to device access (e.g., treatment of limb ischemia, etc.) or recurrent/ongoing myocardial ischemia (i.e., additional PCI or CABG after exit from catheterization lab)
Intended performance of the device:
No severe hypotension, defined as: SBP or augmented diastolic pressure (whichever is greater) &lt; 90 mmHg while on device support requiring (1) more than one administration of OR (2) continuous infusion of inotropic/pressor medications to restore hemodynamics
Complete revascularization of all ischemia-producing lesions achieved as planned (i.e., complete planned revascularization achieved)
No structural cardiac device complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants with re-hospitalizations, re-interventions, or surgery for the underlying condition (e.g. ischemic coronary artery disease)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life questionnaires from baseline to 90 days - EQ-5D-5L</measure>
    <time_frame>90 days</time_frame>
    <description>The EQ-5D-5L consists of scores from 2 methods: the descriptive system and the visual analogue scale (VAS). Questionnaire in the the descriptive system covers the following dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The VAS records the respondents' self-rated heath on a 20-cm vertical, visual analogue scale with endpoints labelled &quot;the best health you can imagine&quot; and &quot;the worst health you can imagine.&quot;
The descriptive system will have a summarized index value, ranging from 0 to 1, and the VAS will have a score ranging from 0 to 100. For each score, the higher the score, the better. The more positive change from baseline, the better the treatment effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life questionnaires from baseline to 90 days - Seattle Angina Questionnaire (SAQ)</measure>
    <time_frame>90 days</time_frame>
    <description>There are 5 summary scores within the SAQ, which cover the 5 domains as follows.
Physical limitation
Angina stability
Angina frequency
Treatment satisfaction
Quality of life
The range of the score of SAQ will be 0-100 for each of the 5 domains. The higher the score, the better. The more positive change from baseline, the better the treatment effect.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">716</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>HeartMate PHP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The HeartMate PHP System is a temporary (&lt;6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is an acceptable therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Any Abiomed Impella® device approved for use in high-risk PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Any Abiomed Impella® Device approved for use in high-risk PCI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HeartMate PHP</intervention_name>
    <description>The HeartMate PHP System is a temporary (&lt;6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is an acceptable therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events.</description>
    <arm_group_label>HeartMate PHP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Any Abiomed Impella® device approved for use in high-risk PCI</intervention_name>
    <description>Any Abiomed Impella® device approved for use in high-risk PCI.</description>
    <arm_group_label>Any Abiomed Impella® device approved for use in high-risk PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Subject is undergoing elective or urgent high risk PCI procedure and is
             hemodynamically stable

          -  Subject is indicated for a revascularization of at least one de novo or restenotic
             lesion in a native coronary vessel or bypass graft

          -  A heart team, including a cardiac surgeon, has determined high risk PCI is an
             acceptable therapeutic option

          -  Subject must provide written informed consent prior to any clinical investigation
             related procedure

        Imaging Inclusion Criteria:

        • The presence of complex coronary artery disease (CAD) makes hemodynamic instability
        resulting from repeat episodes of reversible myocardial ischemia during PCI likely. Complex
        CAD is defined as an ejection fraction of &lt;50% by echocardiographic assessment AND at least
        one of the following:

          -  intervention of the last patent coronary conduit, OR

          -  intervention of an unprotected left main artery, OR

          -  intervention on patient presenting with triple vessel disease defined as at least one
             significant stenosis (at least 50% diameter stenosis on visual assessment) in all
             three major epicardial territories

        Exclusion Criteria:

          -  Emergency PCI

          -  Any prior coronary revascularization within the last 6 months

          -  Any MI with elevated cardiac biomarker (creatinine kinase-MB (CK-MB) or troponin &gt;1X
             upper limit of normal (ULN)) and no evidence of at least 1 consecutive CKMB or
             troponin value trending downward from previous value (at least 4 hours apart) OR ST
             Elevation MI (STEMI) within 72 hours prior to the index procedure regardless of the
             level of cardiac biomarker

          -  Cardiac arrest within 24 hours of procedure requiring cardiopulmonary resuscitation
             (CPR) or defibrillation

          -  Any use of a mechanical circulatory support device within 14 days prior to the index
             procedure (Note: Subjects must be hemodynamically stable without any hemodynamic
             support to be eligible for this clinical investigation.)

          -  Hemodynamic support with a mechanical circulatory support device (e.g.the HeartMate
             PHP, Impella, intra-aortic balloon pump (IABP), or extra-corporeal membrane
             oxygenation (ECMO)) post-PCI is anticipated.

          -  Any condition that requires discontinuation of antiplatelet and/or anticoagulant
             therapy within 90 days following the index procedure (e.g. planned noncardiac surgery)

          -  Any use of vasopressors or inotropes within 24 hours prior to the index procedure

          -  Staged PCI is planned within 90 days following device removal.

          -  Cardiogenic shock (SBP &lt;90 mmHg for &gt;1 hour with either cool clammy skin OR oliguria
             OR altered sensorium AND cardiac index &lt;2.2 L/min/m2)

          -  History of aortic valve replacement or repair

          -  Severe peripheral vascular disease that will preclude the use of a 14F access sheath,
             which is required for the insertion of the HeartMate PHP catheter

          -  Known abnormalities of the aorta that would preclude surgery, including aneurysms and
             significant tortuosity or calcifications

          -  Subject is on hemodialysis.

          -  Liver dysfunction with elevation of liver enzymes and bilirubin levels to ≥ 3X ULN or
             Internationalized Normalized Ratio (INR) ≥1.6 or lactate dehydrogenase (LDH) &gt; 2.5X
             ULN

          -  Abnormal coagulation parameters (platelet count ≤75000/mm3 or INR ≥1.6 or fibrinogen
             ≤1.5 g/l)

          -  Active systemic infection requiring treatment with antibiotics

          -  Stroke or transient ischemic attack (TIA) within 6 months of procedure

          -  Any allergy or intolerance to ionic and nonionic contrast media, anticoagulants
             (including heparin), or antiplatelet therapy drugs that cannot be adequately
             premedicated

          -  Subject is pregnant (For a female subject of childbearing potential, a pregnancy test
             must be performed within 14 days (≤14 days) prior to the index procedure per site
             standard test).

          -  Participation in another clinical study of an investigational drug or device that has
             not met its primary endpoint

          -  Presence of other anatomic or comorbid conditions, or other medical, social, or
             psychological conditions that, in the investigator's opinion, could limit the
             subject's ability to participate in the clinical investigation or to comply with
             followup requirements, or impact the scientific soundness of the clinical
             investigation results

          -  Life expectancy &lt;1 year

        Imaging Exclusion Criteria:

          -  Mural thrombus in the left ventricle

          -  Documented present of aortic stenosis (orifice area of 1.52 cm^2 or less)

          -  Moderate to severe aortic insufficiency by echocardiographic assessment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessie Coe</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stacy Scribner</last_name>
    <phone>651-756-5602</phone>
    <email>Stacy.Scribner@Abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessie Coe</last_name>
    <phone>224-668-5360</phone>
    <email>jessie.coe@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Scottsdale Shea Medical Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joanne Saczynski</last_name>
      <phone>480-323-3390</phone>
      <email>jsaczynski@HonorHealth.com</email>
    </contact>
    <investigator>
      <last_name>David Rizik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sobeyda Cruz</last_name>
      <email>marquez@shc.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Deepak Acharya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC University Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa Ramos</last_name>
      <email>melissa.ramos@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Ray Matthews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bonnie Paul</last_name>
      <email>bonnie.paul@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Raj Makkar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St.Joseph Hospital</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Chung</last_name>
      <email>Sandy.Chung@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>Brian Kolski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bonni Lang</last_name>
      <email>blang@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Mauricio Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orlando Regional Medical Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ashley Dupont</last_name>
      <email>ashley.dupont@orlandohealth.com</email>
    </contact>
    <investigator>
      <last_name>Vijaykumar Kasi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Heart Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Picardi</last_name>
      <email>kristina.picardi@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Vivek Rajagopal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caitlin Brady</last_name>
      <email>cbrady1@nm.org</email>
    </contact>
    <investigator>
      <last_name>Mark Ricciardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margaret Lee</last_name>
      <email>mlee3@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Sandeep Nathan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iowa Heart Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Megan Murphy</last_name>
      <email>mmurphy@iowaheart.com</email>
    </contact>
    <investigator>
      <last_name>David Mcallister, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacob Simon</last_name>
      <email>jsimo9@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Murtuza Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shannon Williams</last_name>
      <email>slwilliams@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>James S Jenkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vilma Castaneda</last_name>
      <email>vcastaneda@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Navin Kapur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lina Fu</last_name>
      <email>lfu2@partners.org</email>
    </contact>
    <investigator>
      <last_name>Ignacio Inglessis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconness Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Kaufman</last_name>
      <email>jmkaufma@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Roger Laham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margaret Fox</last_name>
      <email>mfox2@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Akshay Khandelwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Butterworth Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abbey Mulder</last_name>
      <email>Abbey.Mulder@spectrumhealth.org</email>
    </contact>
    <investigator>
      <last_name>David Wohns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Coley Landvik</last_name>
      <email>CLandvik@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Ganesh Raveendran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristin Eads</last_name>
      <email>keads@hmhs.net</email>
    </contact>
    <investigator>
      <last_name>Barry Bertolet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Lacy</last_name>
      <email>lnewhouse@saint-lukes.org</email>
    </contact>
    <investigator>
      <last_name>Adam Salisbury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pamela Solon</last_name>
      <email>psolon@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Jasvindar Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Research Institute, Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amanda Gilmore</last_name>
      <email>amanda.gilmore@mercy.net</email>
    </contact>
    <investigator>
      <last_name>Robert F. Merritt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tamara Bernard</last_name>
      <email>tbernard@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Pavlides, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lourdes Cardiology Services</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Danielle Connors</last_name>
      <email>danielle.connors@lmanet.com</email>
    </contact>
    <investigator>
      <last_name>Steve Kernis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Mexico Heart Institute</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sheri Lyver</last_name>
      <email>sherir@nmhi.com</email>
    </contact>
    <investigator>
      <last_name>Raymond Yau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Day</last_name>
      <email>vday@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Johanna Oviedo</last_name>
      <email>joviedo@montefiore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Azeem Latib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maimonides</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gwendolyn Tan-Augenstein, MD</last_name>
      <email>gtan-augenstein@maimonidesmed.org</email>
    </contact>
    <investigator>
      <last_name>Robert Frankel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicole Saint Vrestil</last_name>
      <email>nicole.saintvrestil@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Samin Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Mendez</last_name>
      <email>Jam2407@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Ajay J Kirtane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lori Caufield</last_name>
      <email>lori_caufield@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Frederick Ling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leway Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Haag</last_name>
      <email>elizabeth.haag@chsli.org</email>
    </contact>
    <investigator>
      <last_name>Richard Shlofmitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara Culpepper</last_name>
      <email>sara.culpepper@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Manesh Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Medical Center Clinical Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angelina Pack</last_name>
      <email>apack@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>P. Matthew Belford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Terri Sikora</last_name>
      <email>terri.sikora@thechristhospital.com</email>
    </contact>
    <investigator>
      <last_name>James Kong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carol Knochelmann</last_name>
      <email>carol.knochelmann@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Saad Ahmad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kevin Charnas</last_name>
      <email>kevin.charnas@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Michael Cunningham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luba Mazanec</last_name>
      <email>luba.mazanec@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Lilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integris Baptist Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jill Fife</last_name>
      <email>bethany.fife@integrisok.com</email>
    </contact>
    <investigator>
      <last_name>George Chrysant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Medenilla</last_name>
      <email>Elizabeth.Medenilla@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Saif Anwaruddin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gene Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Singer Research Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kenneth Rayl</last_name>
      <email>kray@wpahs.org</email>
    </contact>
    <investigator>
      <last_name>David Lasorda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Coccio</last_name>
      <email>ecoccio@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Paul Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Stern Cardiovascular Foundation</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Barker</last_name>
      <email>diana.barker@sterncardio.com</email>
    </contact>
    <investigator>
      <last_name>Basil Paulus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centennial Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hallie Hank</last_name>
      <email>hallie.hank@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Taral Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor St. Luke's Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilberto DeFreitas</last_name>
      <email>gilberto.defreitas@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Civitello, MD, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabella Candelaria</last_name>
      <email>isabella.n.candelaria@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Marwan Jumean, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LaShawna Green</last_name>
      <email>lagreen2@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Neal Kleiman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Fitzgerald</last_name>
      <email>andrea.fitzgerald@inova.org</email>
    </contact>
    <investigator>
      <last_name>Alexander Truesdell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Rudloff</last_name>
      <email>cjrudlof@sentara.com</email>
    </contact>
    <investigator>
      <last_name>Deepak Talreja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charlene Boisjolie</last_name>
      <email>Charlene.Boisjolie@swedish.org</email>
    </contact>
    <investigator>
      <last_name>John Petersen II, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katherine Jordan</last_name>
      <email>jordank1@cardiology.washington.edu</email>
    </contact>
    <investigator>
      <last_name>William Lombardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2015</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HeartMate PHP</keyword>
  <keyword>High Risk PCI</keyword>
  <keyword>Mechanical circulatory support device</keyword>
  <keyword>MCS</keyword>
  <keyword>Abbott</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

